Please assess the completion status of the following clinical trial:

Trial Title: Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate at any given point in time during disease history~* CRPC (castration-resistant prostate cancer) with clinical or radiologically confirmed bone progression~* Treatment with 6 injections of radium-223 dichloride 50 kBq/kg and no evidence of progression to bone (according to Prostate Cancer Clinical Trials Working Group 2 \[PCWG2\] criteria) during the first course of treatment~* Signed written informed consent prior to participating in any study related procedures. Willing and able to comply with the protocol, including follow-up visits and examinations~Exclusion Criteria:~* History of a radium-223 dichloride-related serious adverse event (SAE) or CTCAE Grade 3 or 4 adverse event (AE) during or after the initial course of radium-223 dichloride treatment that led to the discontinuation of treatment~* Less than 30 days from the last dose administered in the initial course of radium-223 dichloride treatment~* Visceral metastases 1 cm or greater in largest diameter and / or requiring local or systemic therapeutic intervention, as assessed by abdominal and pelvic magnetic resonance imaging (MRI) / computed tomography (CT) scan and / or chest X-ray within 30 days of the start of treatment~* Lymphadenopathy with lymph nodes exceeding 6 cm in short-axis diameter and / or requiring local or systemic therapeutic intervention. Enlarged lymph nodes of any size if the lymphadenopathy is thought to be a contributor to concurrent hydronephrosis.~* Current central nervous system (CNS) metastases~* Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone)~* Treatment with chemotherapy after the initial course of radium-223 dichloride treatment~* Prior hemibody external radiotherapy~* Prior systemic radiotherapy with strontium-89, samarium-153, rhenium-186, or rhenium-188~* Any other serious illness or medical conditions~  * Crohn's disease or ulcerative colitis~ * History of documented bone marrow dysplasia~ * Unmanageable fecal incontinence~* Imminent or established spinal cord compression based on clinical findings and / or MRI that has not yet been treated~* Other malignancy treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) (Type: EXPERIMENTAL): Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).